International Study of Rare Childhood Cancer Finds Genetic Clues, Potential for Tailored Therapy
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.
International study of rare childhood cancer finds genetic clues, potential for tailored therapy
nih.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nih.gov Daily Mail and Mail on Sunday newspapers.
Memorial Health announces new affiliation
Submitted story
A new Cancer Center on Memorial’s main campus will improve and enhance the patient experience with communal and private treatment areas featuring natural light and outdoor views.
Submitted photo
MARYSVILLE – Memorial Health is continuing its focus and dedication to the fight against cancer, with a mission to bring advanced oncology and hematology services to area residents. Two recent developments in this mission include a formal affiliation with The James Cancer Network (JCN), as well as the opening of a new Cancer Center on its main campus in Marysville.
Memorial recently announced the organization has teamed up with one of the nation’s leading cancer research and care providers, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James), through its James Cancer Network.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time
Precipio, Inc.May 10, 2021 GMT
NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) Specialty diagnostics company Precipio, Inc.(NASDAQ: PRPO), announced that it has launched a new, four-hour Acute Myeloid Leukemia (AML) HemeScreen panel to specifically determine the genetics of this aggressive, acute form of leukemia. When physicians are armed with the genetic character of the disease, they can rapidly and precisely select the most effective targeted therapeutic.
Beyond the important clinical utility and substantial impact to patient care described below, this panel is expected to increase revenues to Oncology Physician Office Laboratories (POLs) by approximately 10% (subject to patient volume), and is expected to similarly increase Precipio’s revenues from existing and future Oncology POL and o